Usha Gutti

About

Master’s in Biotechnology combined with MBA in Health Services Management with 12 years of International and National experience in various institutes/industries including NIH, Harvard Medical School and Novartis Healthcare Pvt. Ltd. Experienced in Stakeholder Management, Project Management, Scientific Writing and Brand Strategy combined with vast experience in Research. Worked in a matrix environment, with proven problem solving and decision making skills including mentoring and training several associates.

Employment

• Novartis Healthcare Ltd Senior Scientific Writer II
  2011 - Present
• Massachusetts General Hospital and Harvard Medical School Research Technologist and Lab Manager
  2008 - 2011
• Uniformed Services University of the Health Sciences Research Associate (US Federal Govt.)
  2007 - 2008
• National Institutes of Health Research Contractor (US Federal Govt.)
  2005 - 2007
• Magene Life Sciences Pvt Ltd Research Associate
  2005 - 2005
• Chemi Labs Microbiologist
  2003 - 2005

Education

• SUNY IT MBA Health Services Management
  2009 - 2011

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• Sequence and structural difference favors a distinct preference of Wnt3a binding with co-receptor LRP6.
  2015 DOI: 10.1080/07391102.2014.991352
  +Save
• Understanding thrombocytopenia: physiological role of microRNA in survival of neonatal megakaryocytes.
  2015 DOI: 10.1007/s11239-015-1238-y
  +Save
• Apoptosis: role in myeloid cell development.
  2015 DOI: 10.5045/br.2015.50.2.73
  +Save
• MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia.
  2015 DOI: 10.1016/j.hemonc.2014.11.008
  +Save
• Wnt Signaling: Role in Regulation of Haematopoiesis
  Indian Journal of Hematology and Blood Transfusion 2015 DOI: 10.1007/s12288-015-0585-3
  +Save
• microRNAs: Key Players in Hematopoiesis.
  2015 DOI: 10.1007/978-3-319-22380-3_10
  +Save
• Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production.
  2013 DOI: 10.1523/JNEUROSCI.0954-13.2013
  +Save
• Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.
  2011 DOI: 10.1074/jbc.M110.198390
  +Save
• MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lung epithelial cell lines.
  2011 DOI: 10.1152/ajplung.00051.2010
  +Save
• Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells.
  2009 DOI: 10.1152/ajplung.90601.2008
  +Save